Overview

A Study of Teclistamab in Combination With Lenalidomide Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Status:
Not yet recruiting

Trial end date:
2032-11-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

Phase:

Phase 3

Details

Lead Sponsor:

European Myeloma Network

Collaborator:

Janssen Pharmaceutica

Treatments:

Lenalidomide